Uterine leiomyosarcoma may be rare, but awareness can save lives. If you or someone you love is experiencing persistent or ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Canada is among countries that have made it a goal to eliminate cervical cancer by or before 2040, but between 2015 and 2019 ...

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a survival benefit in a confirmatory phase 3 trial.

In both studies, the PD-1 inhibitors plus chemotherapy were compared to chemo plus placebo and showed they were more effective at extending progression-free survival (PFS). In RUBY, Jemperli ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

Jeff Bridges shared that he is feeling "very good" in remission nearly five years after being diagnosed with lymphoma, a form of blood cancer.

Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR ...

Claire O'Shea, 42, from Cardiff, was diagnosed with irritable bowel syndrome (IBS) but a masseuse on a Turkish holiday told ...

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

A “crisis” in cancer treatment wait times has prompted the opening of a second operating room for gynecological cancers at ...

"Although it is a serious disease, I feel fortunate that I have a great team of doctors and the prognosis ... of being cancer-free in January. The mother of two was diagnosed with endometrial ...